Randall Michael Giuffre - 15 Jul 2021 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Director
Signature
/s/ Amy Culbert, attorney-in-fact
Issuer symbol
DMAC
Transactions as of
15 Jul 2021
Net transactions value
$0
Form type
4
Filing time
16 Jul 2021, 16:52:09 UTC
Next filing
03 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 116,029 15 Jul 2021 Direct F1
holding DMAC Voting Common Shares, no par value per share 5,165 15 Jul 2021 See footnote F2
holding DMAC Voting Common Shares, no par value per share 21,070 15 Jul 2021 By Spouse
holding DMAC Voting Common Shares, no par value per share 54,186 15 Jul 2021 By Children

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Award $0 +9,393 $0.000000 9,393 15 Jul 2021 Common Shares 9,393 $3.64 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 15,225 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 36,498 voting common shares held by Michael Giuffre and his wife jointly and 60,160 voting common shares held by Michael Giuffre individually.
F2 These voting common shares are held by 424822 Albert Ltd, of which Michael Giuffre has sole voting and dispositive power.
F3 Vests in four nearly equal quarterly installments over one year.